Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies

Frameshift (+1) proteins such as APP+1 and UBB+1 accumulate in sporadic cases of Alzheimer disease (AD) and in older subjects with Down syndrome (DS). We investigated whether these proteins also accumulate at an early stage of neuropathogenesis in young DS individuals without neuropathology and in early-onset familial forms of AD (FAD), as well as in other tauopathies, such as Pick disease (PiD) or progressive supranuclear palsy (PSP). APP+1 is present in many neurons and beaded neurites in very young cases of DS, which suggests that it is axonally transported. In older DS patients (>37 years), a mixed pattern of APP+1 immunoreactivity was observed in healthy looking neurons and neurites, dystrophic neurites, in association with neuritic plaques, as well as neurofibrillary tangles. UBB+1 immunoreactivity was exclusively present in AD type of neuropathology. A similar pattern of APP+1 and UBB+1 immunoreactivity was also observed for FAD and much less explicit in nondemented controls after the age of 51 years. Furthermore, we observed accumulation of +1 proteins in other types of tauopathies, such as PiD, frontotemporal dementia, PSP and argyrophylic grain disease. These data suggest that accumulation of +1 proteins contributes to the early stages of dementia and plays a pathogenic role in a number of diseases that involve the accumulation of tau.

[1]  Bin Zhang,et al.  Axonal transport defects: a common theme in neurodegenerative diseases , 2005, Acta Neuropathologica.

[2]  G. Vattemi,et al.  Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers , 2004, Neurology.

[3]  R. Roos,et al.  Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. , 2004, Human molecular genetics.

[4]  E. Hol,et al.  Frame‐shifted amyloid precursor protein found in Alzheimer's disease and Down's syndrome increases levels of secreted amyloid β40 , 2004, Journal of neurochemistry.

[5]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[6]  C. Almeida,et al.  Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain , 2004, The Journal of Neuroscience.

[7]  D. Wagner,et al.  Proteasome inhibition arrests neurite outgrowth and causes “dying‐back” degeneration in primary culture , 2003, Journal of neuroscience research.

[8]  W. Engel,et al.  Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-&bgr;, misfolded proteins, predisposing genes, and aging , 2003, Current opinion in rheumatology.

[9]  E. Hol,et al.  Disease‐specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  E. Hol,et al.  Frameshifted β-Amyloid Precursor Protein (APP+1) Is a Secretory Protein, and the Level of APP+1 in Cerebrospinal Fluid Is Linked to Alzheimer Pathology* , 2003, Journal of Biological Chemistry.

[11]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[12]  S. Kim,et al.  Essential Role of E2-25K/Hip-2 in Mediating Amyloid-β Neurotoxicity , 2003 .

[13]  G. Leuba,et al.  Tau and neurofilaments in a family with frontotemporal dementia unlinked to chromosome 17q21–22 , 2003, Neurobiology of Disease.

[14]  Cornelia M van Duijn,et al.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. , 2002, The American journal of pathology.

[15]  E. Hol,et al.  Molecular misreading of the ubiquitin B gene and hepatic mallory body formation. , 2002, Gastroenterology.

[16]  E. Hol,et al.  Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation , 2002, The Journal of cell biology.

[17]  Julio C. Echegoyen,et al.  Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Hol,et al.  Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  T. Bayer,et al.  Homodimerization of Amyloid Precursor Protein and Its Implication in the Amyloidogenic Pathway of Alzheimer's Disease* , 2001, The Journal of Biological Chemistry.

[20]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[21]  M. Hersberger,et al.  A dinucleotide deletion in amyloid precursor protein (APP) mRNA associated with sporadic Alzheimer's disease results in efficient secretion of truncated APP isoforms from neuroblastoma cell cultures , 2001, Journal of neurochemistry.

[22]  G. Leuba,et al.  Familial frontotemporal dementia with ubiquitin inclusion bodies and without motor neuron disease , 2000, Acta Neuropathologica.

[23]  P. Davies,et al.  Conformational change as one of the earliest alterations of tau in Alzheimer’s disease , 2000, Neurobiology of Aging.

[24]  C. Pickart,et al.  Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Hol,et al.  Molecular misreading in non‐neuronal cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  H. Yamaguchi,et al.  Age-related plaque morphology and C-terminal heterogeneity of amyloid β in Dutch-type hereditary cerebral hemorrhage with amyloidosis , 2000, Acta Neuropathologica.

[27]  G. Leuba,et al.  No Detected Mutations in the Genes for the Amyloid Precursor Protein and Presenilins 1 and 2 in a Swiss Early-Onset Alzheimer’s Disease Family with a Dominant Mode of Inheritance , 1999, Dementia and Geriatric Cognitive Disorders.

[28]  E. Scherder,et al.  Reduced neuronal activity and reactivation in Alzheimer's disease , 1998, European Neuropsychopharmacology.

[29]  A. Hofman,et al.  Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala→Gly mutation , 1998, Acta Neuropathologica.

[30]  Y. Ihara,et al.  Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques , 1998, Acta Neuropathologica.

[31]  F. Grosveld,et al.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.

[32]  S. Ochs,et al.  The origin and nature of beading: A reversible transformation of the shape of nerve fibers , 1997, Progress in Neurobiology.

[33]  T. Iwatsubo,et al.  Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.

[34]  M. Cruts,et al.  Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. , 1995, Human molecular genetics.

[35]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[36]  C. van Broeckhoven,et al.  Early‐onset Alzheimer's disease in 2 large Belgian families , 1991, Neurology.

[37]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[38]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[39]  D. Ron,et al.  Conformational disease , 2000, Nature Cell Biology.

[40]  C. van Broeckhoven Alzheimer's disease: identification of genes and genetic risk factors. , 1998, Progress in brain research.

[41]  S. Hirai,et al.  Immunohistochemical analysis of COOH-termini of amyloid beta protein (Aβ) using end-specific antisera for Aβ40 and Aβ42 in Alzheimer's disease and normal aging , 1995 .